Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | Outperform → Mkt Perform | William Blair | |
| 3/3/2022 | Outperform → Market Perform | Cowen & Co. | |
| 11/24/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
3 - NuCana plc (0001709626) (Issuer)
3 - NuCana plc (0001709626) (Issuer)
3 - NuCana plc (0001709626) (Issuer)
S-8 - NuCana plc (0001709626) (Filer)
20-F - NuCana plc (0001709626) (Filer)
6-K - NuCana plc (0001709626) (Filer)
William Blair downgraded NuCana from Outperform to Mkt Perform
Cowen & Co. downgraded NuCana from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our P
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We recently announced promising data for both NUC-7738 and NUC-3373 that continue to support the potential of our ProTides to deliver
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and
SC 13G/A - NuCana plc (0001709626) (Subject)
SC 13D/A - NuCana plc (0001709626) (Subject)
SC 13G/A - NuCana plc (0001709626) (Subject)